MeiraGTx Holdings plc
http://meiragtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MeiraGTx Holdings plc
New Pink Sheet PRIME Tracker Reveals The Companies With The Most Entries On EMA Scheme
Securing a place on the European Medicines Agency’s priority medicines scheme is not easy, but some companies have managed to make the grade more than once.
Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
Aldeyra Thinks It May Have Broadly Applicable Retinitis Pigmentosa Therapy
Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.
Beacon Makes £96m Debut With Gene Therapy Pipeline For Unmet Retinal Needs
The UK firm’s substantial series A raise will help it advance a pipeline of gene therapy candidates for both rare and common retinal conditions, including a Phase II candidate rescued from a struggling biotech.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Athena Vision
- MeiraGTx Ltd.
- MeiraGTx UK II Limited
- Vector Neurosciences Inc.
- Vector Neurosciences, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice